ID   SKBR3/TDR
AC   CVCL_B3MN
DR   cancercelllines; CVCL_B3MN
DR   Wikidata; Q110433236
RX   CelloPub=CLPUB00650;
RX   PubMed=28821558;
CC   Population: Caucasian.
CC   Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1).
CC   Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 05-10-23; Version: 5
//
RX   CelloPub=CLPUB00650;
RA   Sabbaghi Mehrjardi M.A.;
RT   "Uncovering mechanisms of acquired resistance to trastuzumab-emtansine
RT   (T-DM1) in HER2 positive breast cancer.";
RL   Thesis PhD (2017), Universitat de Barcelona, Spain.
//
RX   PubMed=28821558; DOI=10.1158/1078-0432.CCR-17-0696;
RA   Sabbaghi Mehrjardi M.A., Gil-Gomez G., Guardia C., Servitja S.,
RA   Arpi O., Garcia-Alonso S., Menendez S., Arumi-Uria M., Serrano L.,
RA   Salido M., Muntasell A., Martinez-Garcia M., Zazo S., Chamizo C.,
RA   Gonzalez-Alonso P., Madoz-Gurpide J., Eroles P., Arribas J.,
RA   Tusquets I., Lluch A., Pandiella A., Rojo F., Rovira A., Albanell J.;
RT   "Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1)
RT   acquired resistance in HER2-positive breast cancer.";
RL   Clin. Cancer Res. 23:7006-7019(2017).
//